Abstract: A gravitational energy conversion device is configured to rotate or translate on a support surface. The gravitational energy conversion device has a weight and multiple energy converters; the energy converters are mounted around an exterior of the weight and disposed apart from each other. When the weight rotates or translates to make the energy converters contact the support surface, the weight presses down the energy converters due to gravity. When the weight rotates or translates to make the energy converters separate from the support surface, energy in the energy converters is released and transformed into kinetic energy of the weight. Therefore, the device is effective in energy-saving and cushioning.

Abstract: A gravitational energy conversion device for a vehicle has a rotating part and multiple energy converters. The rotating part is rotatably mounted between a vehicle main body and the ground; the energy converters are mounted on an outer annular surface of the rotating part and are disposed apart from each other around the rotating part. Each energy converter has a moving part and a resilient part. The moving part protrudes from the outer annular surface of the rotating part, and is movable toward or away from the rotating part. The resilient part is mounted between the moving part and the rotating part, and drives the moving part to move away from the rotating part.

Abstract: The method is capable of effectively labeling the nanodiamonds with radioactive gallium and can be operated at room temperature, and therefore is convenient to operate and does not require further purification to obtain the nanodiamonds labelled with radioactive gallium with a purity of at least 99%

Abstract: Disclosed herein is a process for chemically synthesizing of hydroquinone derivatives, especially for hydroquinone derivatives with heptadecatrienyl side chain, which is synthesized via a Wittig reaction of 2-(10?-oxononyl)-1,4-diacetoxyl benzene and (3E, 5Z)-3,5-heptadien-1-triphenylphosphonium iodide and then deacetylation. In addition, the product is solid powder.

Abstract: Disclosed herein is a process for chemically synthesizing of hydroquinone derivatives, especially for hydroquinone derivatives with heptadecatrienyl side chain, which is synthesized via a Wittig reaction of 2-(10?-oxononyl)-1,4-diacetoxyl benzene and (3E, 5Z)-3,5-heptadien-1-triphenylphosphonium iodide and then deacetylation. In addition, the product is solid powder.

Abstract: The present invention provides a hexa-lactoside-triazanonane triacetic acid (NOTA) derivative, a method for radiolabeling a hexa-lactoside positron emission tomography (PET) imaging agent for a liver receptor with Ga-68, and a hexa-lactoside PET imaging agent for a liver receptor. The hexa-lactoside-NOTA derivative is a conjugate of six chains of lactose with NOTA obtained by conjugating hexa-lactoside to a chelating agent p-thiocyanate-benzyl-triazanonane diacetic acid-glutamic acid in the presence of triethyl amine/dimethyl formamide as a solvent. The radiolabeling method comprises labeling with Ga-68 at room temperature. According to the present invention, the labeling effect is stable, the labeling efficiency of the labeled product is greater than 95%, the labeled product is highly stable and the radiochemical purity is still greater than 90% after 4 hours.

Abstract: The present invention relates to a hydroxamic acid-based contrast agent containing an isotope of fluorine, which comprises a compound having a structure of Formula (III): wherein R1 represents radioactive fluorine-18 (18F) or isotope fluorine-19 (19F), and R2 represents hydroxyamine —(NH)OH. The hydroxamic acid-based contrast agent containing an isotope of fluorine provided in the present invention has the capability of selectively inhibiting histone deacetylase (HDAC) subtypes 8/6/3, and specifically targets to the focus of spinocerebellar ataxia with over-activation of HDAC. By labeling with the radioisotope fluorine-18, a positron emission tomography (PET) image is obtained with the hydroxamic acid-based contrast agent containing radioisotope fluorine-18, whereby spinocerebellar ataxia is effectively detected.

Abstract: An aspect includes receiving a transaction scope generated for a process in response to processing in a critical section and receiving collected data related to the process. Requests are generated using the collected data. The requests and data are stored as pending items chained together to form an ordered list in a private storage during critical section processing. The requests are processed based on the transaction scope, the processing including implementing a check of the process for any pending items in response to a transaction scope application programming interface being called or other processing relating to the pending items. The pending items are processed in the order they are created by using the ordered list. One of the requests is a rollback request that includes at least one of removing the pending items from the private storage, releasing the private storage for all pending items, and resuming normal processing.

Abstract: The present invention provides a hexa-lactoside-triazanonane triacetic acid (NOTA) derivative, a method for radiolabeling a hexa-lactoside positron emission tomography (PET) imaging agent for a liver receptor with Ga-68, and a hexa-lactoside PET imaging agent for a liver receptor. The hexa-lactoside-NOTA derivative is a conjugate of six chains of lactose with NOTA obtained by conjugating hexa-lactoside to a chelating agent p-thiocyanate-benzyl-triazanonane diacetic acid-glutamic acid in the presence of triethyl amine/dimethyl formamide as a solvent. The radiolabeling method comprises labeling with Ga-68 at room temperature. According to the present invention, the labeling effect is stable, the labeling efficiency of the labeled product is greater than 95%, the labeled product is highly stable and the radiochemical purity is still greater than 90% after 4 hours.

Abstract: Disclosed herein are a multivalent saccharide complex, a radioactive multivalent saccharide complex contrast agent and use thereof. The multivalent saccharide complex has a chelator, a linker, and glucose, and is configured to diagnose and evaluate the therapeutic effect of cancers.

Abstract: The present invention relates to a hydroxamic acid-based contrast agent containing an isotope of fluorine, which comprises a compound having a structure of Formula (III): wherein R1 represents radioactive fluorine-18 (18F) or isotope fluorine-19 (19F), and R2 represents hydroxyamine —(NH)OH. The hydroxamic acid-based contrast agent containing an isotope of fluorine provided in the present invention has the capability of selectively inhibiting histone deacetylase (HDAC) subtypes 8/6/3, and specifically targets to the focus of spinocerebellar ataxia with over-activation of HDAC. By labeling with the radioisotope fluorine-18, a positron emission tomography (PET) image is obtained with the hydroxamic acid-based contrast agent containing radioisotope fluorine-18, whereby spinocerebellar ataxia is effectively detected.

Abstract: Disclosed herein are a multivalent saccharide complex, a radioactive multivalent saccharide complex contrast agent and use thereof. The multivalent saccharide complex has a chelator, a linker, and glucose, and is configured to diagnose and evaluate the therapeutic effect of cancers.

Abstract: An aspect includes receiving a transaction scope generated for a process in response to processing in a critical section and receiving collected data related to the process. Requests are generated using the collected data. The requests and data are stored as pending items chained together to form an ordered list in a private storage during critical section processing. The requests are processed based on the transaction scope, the processing including implementing a check of the process for any pending items in response to a transaction scope application programming interface being called or other processing relating to the pending items. The pending items are processed in the order they are created by using the ordered list. One of the requests is a rollback request that includes at least one of removing the pending items from the private storage, releasing the private storage for all pending items, and resuming normal processing.

Abstract: According to one or more embodiments, a system and computer implemented method for managing critical section processing are provided. The method includes generating, using a processor, a transaction scope for a process in response to processing in a critical section, collecting data related to the process, generating, using the processor, a request using the collected data, storing the request and data as a pending item in a private storage during critical section processing, and processing, using the processor, the request based on the transaction scope.

Abstract: Disclosed herein are a novel polymer, a thermosensitive carrier prepared using the same and use thereof. The novel polymer is essentially composed of a PEO-PPO-PEO block copolymer and silane.

Abstract: The present invention provides a method for preparing a 6-aminohexyl lactoside-NOTA conjugate. The preparation method comprises brominating perbenzoylated lactose with hydrobromic acid; glycosylating 6-azidohexanol to obtain 6-azidohexyl perbenzoyl lactoside; and deprotecting this precursor in two steps to obtain 6-aminohexyl lactoside and conjugating 6-aminohexyl lactoside to NCS-benzyl-NODA GA (i.e. 2,2?-(7-(1-carboxy-4-((4-isothiocyanate benzyl) amino)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl) diacetic acid) in triethyl amine as an alkaline solvent, to obtain a 6-aminohexyl lactoside-NCS-benzyl-NODA GA conjugate. In this novel preparation method, no deglycosylated side product is produced, such that the yield is considerably increased to 46%. Therefore, the method is suitable for future massive production since the requirement for repeated preparations for massive production is reduced, and the impurities produced in the previously scaled-up preparation process are not present.

Abstract: The invention discloses a high-yield method for preparing a ribonucleic acid (RNA)-diethyltriamine pentaacetic acid (DTPA) conjugate. The conjugate is prepared by conjugating a RNA or locked nucleic acid (LNA) having an amino group to p-isothiocyanate benzyl-DTPA (SCN-Bn-DTPA) or DTPA anhydride with heating under microwave.

Abstract: According to one or more embodiments, a system and computer implemented method for managing critical section processing are provided. The method includes generating, using a processor, a transaction scope for a process in response to processing in a critical section, collecting data related to the process, generating, using the processor, a request using the collected data, storing the request and data as a pending item in a private storage during critical section processing, and processing, using the processor, the request based on the transaction scope.

Abstract: The invention discloses a high-yield method for preparing a ribonucleic acid (RNA)-diethyltriamine pentaacetic acid (DTPA) conjugate. The conjugate is prepared by conjugating a RNA or locked nucleic acid (LNA) having an amino group to p-isothiocyanate benzyl-DTPA (SCN-Bn-DTPA) or DTPA anhydride with heating under microwave.

Abstract: The present invention provides a method for preparing a 6-aminohexyl lactoside-NOTA conjugate. The preparation method comprises brominating perbenzoylated lactose with hydrobromic acid; glycosylating 6-azidohexanol to obtain 6-azidohexyl perbenzoyl lactoside; and deprotecting this precursor in two steps to obtain 6-aminohexyl lactoside and conjugating 6-aminohexyl lactoside to NCS-benzyl-NODA GA (i.e. 2,2?-(7-(1-carboxy-4-((4-isothiocyanate benzyl) amino)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl) diacetic acid) in triethyl amine as an alkaline solvent, to obtain a 6-aminohexyl lactoside-NCS-benzyl-NODA GA conjugate. In this novel preparation method, no deglycosylated side product is produced, such that the yield is considerably increased to 46%. Therefore, the method is suitable for future massive production since the requirement for repeated preparations for massive production is reduced, and the impurities produced in the previously scaled-up preparation process are not present.